文献速递颈动脉与弓上血管

经颈动脉血运重建与经股动脉颈动脉支架置入术后死亡决定因素及中期结局

Determinants of Mortality and Mid-Term Outcomes After Transcarotid Artery Revascularization and Transfemoral Carotid Artery Stenting.
PubMed 文献 · J Endovasc Ther · 2024-03-06

基于血管质量倡议2016年1月至2022年12月数据,纳入70237例接受经颈动脉血运重建(TCAR)或经股动脉颈动脉支架置入(tfCAS)的患者,经倾向性评分匹配后比较3年结局。TCAR与tfCAS相比3年死亡风险降低24%(HR=0.76,95%CI=0.71-0.82,p<0.001),生存优势主要在前6个月确立,术后卒中为30天和1年死亡的主要独立预测因素。

要点

  • TCAR较tfCAS的3年死亡风险降低24%(HR=0.76,95%CI=0.71-0.82,p<0.001),症状性和无症状患者均一致。
  • 生存优势主要在前6个月确立(HR=0.59,95%CI=0.53-0.62,p<0.001),6至36个月无差异(HR=0.95,95%CI=0.86-1.05,p=0.31)。
  • 术后卒中为TCAR后30天和1年死亡的主要独立预测因素。

核心结论

  • TCAR较tfCAS具有持续的中期生存优势,该获益主要在前6个月内确立。
  • 术后卒中是TCAR后30天和1年死亡的主要独立预测因素。

研究设计与样本

  • 基于血管质量倡议数据库分析2016年1月至2022年12月接受TCAR或tfCAS的患者。
  • 共纳入70237例患者(TCAR=58.7%,tfCAS=41.3%),采用1:1倾向性评分最邻近匹配。
  • 匹配后得到22322对,除TCAR组年龄更大(71.6岁 vs 70.8岁)外两组无主要差异。
  • 采用Kaplan-Meier生存分析和Cox比例风险回归评估长期结局,采用迭代逐步多元logistic回归和Cox回归识别30天和1年死亡的预测因素。

主要发现

  • 3年时TCAR较tfCAS死亡风险降低24%(HR=0.76,95%CI=0.71-0.82,p<0.001),症状性和无症状患者均一致。
  • 生存优势在前6个月确立(HR=0.59,95%CI=0.53-0.62,p<0.001),6至36个月死亡风险无差异(HR=0.95,95%CI=0.86-1.05,p=0.31)。
  • TCAR较tfCAS 3年卒中风险降低(HR=0.81,95%CI=0.66-0.99,p=0.04)。
  • TCAR较tfCAS 3年卒中或死亡风险降低(HR=0.81,95%CI=0.76-0.87,p<0.001)。
  • 30天和1年死亡的首要预测因素为术后并发症,主要独立预测因素为术后卒中。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The potential benefit of transcarotid artery revascularization (TCAR) over transfemoral carotid artery stenting (tfCAS) has been studied in the perioperative period with lower rates of stroke and death; however, data on mid-term outcomes are limited. We aimed to evaluate 3-year outcomes after TCAR and tfCAS and determine the primary predictors of 30-day and 1-year mortality following TCAR. METHODS: Data from the Vascular Quality Initiative for patients undergoing TCAR or tfCAS from January 2016 to December 2022 were analyzed. 1:1 propensity score matching using the nearest-neighbor method was used to adjust baseline demographics and clinical characteristics. Kaplan-Meier survival analysis and Cox Proportional Hazard Regression were used to evaluate long-term outcomes. Iterative stepwise multiple logistic regression analysis and Cox Proportional Hazard Regression were used to identify predictors of 30-day and 1-year mortality, respectively, based upon preoperative, intraoperative, and postoperative factors. RESULTS: A total of 70 237 patients were included in analysis (TCAR=58.7%, tfCAS=41.3%). Transcarotid artery revascularization patients were older and had higher rates of comorbid conditions and high-risk medical and anatomic features than tfCAS patients. Propensity score matching yielded 22 322 pairs with no major differences between groups except that TCAR patients were older (71.6 years vs 70.8 years). At 3 years, TCAR was associated with a 24% reduction in hazard of death compared with tfCAS (hazard ratio [HR]=0.76, 95% confidence interval [CI]=0.71-0.82, p<0.001), for both symptomatic and asymptomatic patients. This survival advantage was established in the first 6 months (HR=0.59, 95% CI=0.53-0.62, p<0.001), with no difference in mortality risk from 6 months to 36 months (HR=0.95, 95% CI=0.86-1.05, p=0.31). Transcarotid artery revascularization was also associated with decreased hazard for 3-year stroke (HR=0.81, 95% CI=0.66-0.99, p=0.04) and stroke or death (HR=0.81, 95% CI=0.76-0.87, p<0.001) compared with tfCAS. The top predictors for 30-day and 1-year mortality were postoperative complications. The primary independent predictor was the occurrence of postoperative stroke. CONCLUSIONS: Transcarotid artery revascularization had a sustained mid-term survival advantage associated over tfCAS, with the benefit being established primarily within the first 6 months. Notably, our findings highlight the importance of postoperative stroke as the primary independent predictor for 30-day and 1-year mortal.Clinical ImpactThe ongoing debate over the superiority of TCAR compared to tfCAS and CEA has been limited by a lack of comparative studies examining the impact of pre-operative symptoms on outcomes. Furthermore, data are scarce on mid-term outcomes for TCAR beyond the perioperative period. As a result, it remains uncertain whether the initial benefits of stroke and death reduction observed with TCAR over tfCAS persist beyond one year. Our study addresses these gaps in the literature, offering evidence to enable clinicians to assess the efficacy of TCAR for up to three years. Additionally, our study seeks to identify risk factors for postoperative mortality following TCAR, facilitating optimal patient stratification.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Zhu J, Rao A, Berger K, et al. Determinants of Mortality and Mid-Term Outcomes After Transcarotid Artery Revascularization and Transfemoral Carotid Artery Stenting. J Endovasc Ther. 2024. PMID: 38449352. doi:10.1177/15266028241235791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。